With the support of the Regional University-Industry Technology Transfer Center for Biopharmaceuticals (Suzhou, Jiangsu) in SIP, the research team led by Prof. Gu Yueqing at China Pharmaceutical University signed a technology transfer agreement with the Suzhou-based Jiangsu Huayi Technology Co Ltd to jointly commercialize a positron-based nuclear medicine technology.
The tie-up followed a presentation on the technology at a project roadshow held by the center and a series of subsequent efforts it made to evaluate and verify the technology and find the partner for its commercialization.
Huayi Technology has demonstrated excellence in developing, manufacturing and distributing high-quality radiopharmaceutical products. It is expected to help pave a critical path for the laboratory breakthrough to enter market.
Concurrently, Prof. Gu’s team signed a preliminary agreement with the center to base its original diagnostic and therapeutic nuclear medicine project in it.
December 4, 2025
